All Pharmaceuticals articles – Page 6
-
ArticlePurdue Pharma case more than an $8B fine
Compliance officers in the pharmaceutical and healthcare industries should look beyond the $8 billion fine Purdue Pharma received from the DOJ and at the bigger enforcement trend highlighting the need for better oversight in the field.
-
ArticleMass. pharma company will pay $20.75M to settle FCA lawsuit
A Massachusetts-based pharmaceutical company will pay $20.75 million settle a whistleblower’s allegations that the company knowingly promoted misleading instructions for a skin lesion drug that caused doctors to submit false claims to Medicare.
-
ArticleBausch Health to pay $45M for misleading disclosures
The Securities and Exchange Commission charged Bausch Health (formerly Valeant Pharmaceuticals) and three former executives for improper revenue recognition and misleading disclosures in SEC filings and earnings presentations.
-
ArticleTaro Pharma to pay $206M to resolve price-fixing charges
Taro Pharmaceuticals will pay a $205.7 million criminal penalty to resolve charges as part of the Justice Department’s ongoing investigation into the generic pharmaceutical industry.
-
Article
Akcea appoints chief compliance officer
Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, announced Tracy Palmer Berns has joined the company as chief compliance officer.
-
ArticleNovartis’ latest settlements: $729M in kickback charges
A week after resolving FCPA investigations for $347 million, Swiss pharmaceutical drug maker Novartis will pay another $729 million in separate settlements related to kickback schemes.
-
ArticleAlexion Pharmaceuticals to pay $21M to resolve FCPA case
Alexion Pharmaceuticals will pay $21 million to resolve SEC charges that it violated the books and records and internal accounting controls provisions of the FCPA concerning bribes made by subsidiaries to foreign government officials.
-
ArticleNovartis to pay $347M to resolve FCPA investigations
Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.
-
ArticleAlexion nears $25M settlement with SEC in FCPA probe
Alexion Pharmaceuticals said in a regulatory filing that it is nearing a $25 million settlement with the Securities and Exchange Commission concerning an investigation into the company’s compliance with the Foreign Corrupt Practices Act spanning various countries.
-
Article
Zogenix appoints general counsel
Pharmaceutical firm Zogenix announced the appointment of Shawnte Mitchell as executive vice president, general counsel and secretary.
-
Article
ORIC Pharmaceuticals names general counsel
ORIC Pharmaceuticals, a privately held, clinical-stage oncology company, announced Dr. Christian Kuhlen has been named general counsel.
-
Article
Taro appoints accounting chief
Taro Pharmaceutical Industries announced the appointment of Daphne Huang as vice president, CFO and chief accounting officer.
-
Article
Tricida adds chief compliance officer
Pharmaceutical firm Tricida announced the hiring of Robert McKague as executive vice president, general counsel and chief compliance officer.
-
ArticleDOJ intervenes in whistleblower suit against Mallinckrodt
The Department of Justice has intervened in a whistleblower lawsuit against Mallinckrodt over allegations the drug maker knowingly underpaid Medicaid rebates it owed due to significant price increases to its drug Acthar.
-
Article
Trevena tabs chief legal and compliance officer
Biopharmaceutical company Trevena announced the appointment of Scott Applebaum as chief legal and compliance officer and senior vice president of regulatory affairs.
-
ArticlePractice Fusion to overhaul compliance after $145M kickback resolution
Practice Fusion will pay a total of $145 million to resolve criminal and civil investigations for its leading role in an opioid kickback scheme. Particularly notable are the new compliance obligations imposed upon it, which are as weighty and significant as the fine itself.
-
ArticleEurope’s high court strikes blow to drug companies in ‘pay-for-delay’ case
The U.K. Competition and Markets Authority won a victory in a decision by Europe’s high court, ruling GlaxosmithKline’s entering of a financial deal with industry rivals to delay the generic version of its drugs violates EU competition law.
-
Article
Eli Lilly adds general counsel
Pharmaceuticals firm Eli Lilly and Company announced Anat Hakim will join the company as senior vice-president and general counsel.
-
ArticleTeva to pay $54M in FCA whistleblower settlement
Teva Pharmaceuticals has reached a $54 million settlement in a lawsuit filed by two whistleblowers over allegations the drug company bribed physicians through numerous “sham” speaker programs in exchange for prescribing Teva drugs.
-
PremiumTop ethics and compliance failures of 2019
From antitrust and privacy concerns in the tech world to compliance officer liability in the pharmaceutical industry to unethical practices in the banking and accounting professions, more than a dozen companies made Compliance Week’s list of the biggest compliance fails in 2019.